BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28885497)

  • 1. Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.
    Fantus D; Dai H; Ono Y; Watson A; Yokota S; Mohib K; Yoshida O; Ross MA; Watkins SC; Ramaswami B; Valusjkikh A; Rothstein DM; Thomson AW
    Transplantation; 2017 Dec; 101(12):2830-2840. PubMed ID: 28885497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory.
    MacCallum PE; Blundell J
    Psychopharmacology (Berl); 2020 Sep; 237(9):2795-2808. PubMed ID: 32601986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection.
    Rosborough BR; Raïch-Regué D; Liu Q; Venkataramanan R; Turnquist HR; Thomson AW
    Am J Transplant; 2014 Sep; 14(9):2173-80. PubMed ID: 25307040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
    Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
    Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The dual mTORC1/2 inhibitor AZD2014 inhibits acute graft rejection in a rat liver transplantation model].
    Liao H; Wang Y; Xu X; Zhou C; Zhang J; Zhong K; Yang D
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Apr; 42(4):598-603. PubMed ID: 35527497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
    Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
    Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
    Li S; Sheng J; Liu Z; Fan Y; Zhang C; Lv T; Hu S; Jin J; Yu W; Song Y
    J Cell Mol Med; 2021 Mar; 25(5):2436-2449. PubMed ID: 33507584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4(+) memory T cells in mice.
    Liang H; Liao C; Qi Z; Sha C; Xie B; Chen J; Xia J; Wang Y; Yao Q; Zhao Y
    Transpl Immunol; 2010 Feb; 22(3-4):128-36. PubMed ID: 19755159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tanshinol suppresses cardiac allograft rejection in a murine model.
    Lu C; Zeng YQ; Liu H; Xie Q; Xu S; Tu K; Dou C; Dai Z
    J Heart Lung Transplant; 2017 Feb; 36(2):227-236. PubMed ID: 27574736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH.
    Haeryfar SM; Lan Z; Leon-Ponte M; Duffy KR; Ge W; Liu W; Mele T; Garcia B; Wang H
    Transplantation; 2008 Aug; 86(3):460-8. PubMed ID: 18698251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance induction by exosomes from immature dendritic cells and rapamycin in a mouse cardiac allograft model.
    Li X; Li JJ; Yang JY; Wang DS; Zhao W; Song WJ; Li WM; Wang JF; Han W; Zhang ZC; Yu Y; Cao DY; Dou KF
    PLoS One; 2012; 7(8):e44045. PubMed ID: 22952868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
    Cai Y; Tang XD; Zhou PJ
    Scand J Immunol; 2005 Mar; 61(3):266-73. PubMed ID: 15787744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells.
    Nakamura T; Nakao T; Yoshimura N; Ashihara E
    Am J Transplant; 2015 Sep; 15(9):2364-77. PubMed ID: 25943210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR5 blockade in combination with rapamycin prolongs cardiac allograft survival in mice.
    Li J; Zhang K; Ye P; Wang S; Xia J
    Clin Exp Immunol; 2009 Sep; 157(3):437-45. PubMed ID: 19664153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
    Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin.
    Wang H; Qi F; Dai X; Tian W; Liu T; Han H; Zhang B; Li H; Zhang Z; Du C
    Transpl Immunol; 2014 Aug; 31(2):65-74. PubMed ID: 24978830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both
    Liao HF; Lin YZ; Yu CC; Tai TS; Hung SK; Yang CC; Su YC
    Anticancer Res; 2019 Sep; 39(9):4829-4835. PubMed ID: 31519585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance.
    Turnquist HR; Raimondi G; Zahorchak AF; Fischer RT; Wang Z; Thomson AW
    J Immunol; 2007 Jun; 178(11):7018-31. PubMed ID: 17513751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of exogenous interleukin-10 on cardiac allograft survival: inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function.
    Li W; Fu F; Lu L; Narula SK; Fung JJ; Thomson AW; Qian S
    Transplantation; 1999 Nov; 68(9):1402-9. PubMed ID: 10573082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.